EcoDrugPlus

Nuclear Factor Kappa B Subunit 1

Ensembl ID : ENSONIG00000004349
Gene Symbol: NFKB1
1 Cross references
200 Possible Orthologues:

Nuclear Factor, Erythroid 2 Like 2

Ensembl ID : ENSONIG00000008604
Gene Symbol: NFE2L2
4 Cross references
216 Possible Orthologues:

Nuclear Receptor Subfamily 1 Group H Member 3

Ensembl ID : ENSONIG00000005828
Gene Symbol: NR1H3
3 Cross references
391 Possible Orthologues:

Nuclear Receptor Subfamily 1 Group H Member 4

Ensembl ID : ENSONIG00000014678
Gene Symbol: NR1H4
4 Cross references
387 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 1

Ensembl ID : ENSONIG00000008483
Gene Symbol: NR3C1
1 Cross references
205 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 2

Ensembl ID : ENSONIG00000010029
Gene Symbol: NR3C2
4 Cross references
209 Possible Orthologues:

Nucleotide Binding Oligomerization Domain Containing 2

Ensembl ID : ENSONIG00000002837
Gene Symbol: NOD2
3 Cross references
166 Possible Orthologues:

Opioid Receptor Delta 1

Ensembl ID : ENSONIG00000038781
Gene Symbol: OPRD1
3 Cross references
179 Possible Orthologues:

Opioid Receptor Kappa 1

Ensembl ID : ENSONIG00000006128
Gene Symbol: OPRK1
4 Cross references
197 Possible Orthologues:

Oxytocin Receptor

Ensembl ID : ENSONIG00000037102
Gene Symbol: OXTR
1 Cross references
183 Possible Orthologues:

Parathyroid Hormone 1 Receptor

Ensembl ID : ENSONIG00000009467
Gene Symbol: PTH1R
4 Cross references
196 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Alpha

Ensembl ID : ENSONIG00000016715
Gene Symbol: PPARA
2 Cross references
383 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).